2024
Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement
Sundaresan V, Smani S, Rajwa P, Renzulli J, Sprenkle P, Kim I, Leapman M. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39019723, DOI: 10.1016/j.urolonc.2024.06.003.Peer-Reviewed Original ResearchProstate specific antigenProstate cancerPSA-based prostate cancer screeningDiagnostic performanceProstate specific antigen densityProstate specific antigen velocityLow-grade prostate cancerProstate-specific antigen screeningFree prostate specific antigenTreatment of prostate cancerProstate cancer screeningClinical action thresholdsProstate volumeAntigen screeningMalignant cellsSpecific antigenCancer screeningScreening biomarkerProstateClinical roleTest characteristicsCancerClinical applicationClinical thresholdEarly detectionPD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchReliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology
Zeevi T, Leapman M, Sprenkle P, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. IEEE Transactions On Biomedical Engineering 2024, 71: 1084-1091. PMID: 37874731, PMCID: PMC10901528, DOI: 10.1109/tbme.2023.3326799.Peer-Reviewed Original ResearchMagnetic resonance imagingIndividual patientsBiopsy locationProstate biopsy dataBiopsy histopathologyHistopathology scoresPathology scoresBiopsy dataMRI biomarkersTreatment planPatientsResonance imagingProstate regionBiomarkersTherapy treatment plansPathologyRepresentative sampleScoresImaging analysisPrevious studiesHistopathologyProstateCancerClinicians
2023
PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER
Leapman M, Wang R, Long J, Sprenkle P, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.Peer-Reviewed Original ResearchMP75-01 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS AND DIAGNOSIS OF ADVANCED PROSTATE CANCER IN EARLY LIFE
Smani S, Novosel M, Marks V, Jeong F, Sprenkle P, Leapman M. MP75-01 ASSOCIATION BETWEEN SOCIODEMOGRAPHIC FACTORS AND DIAGNOSIS OF ADVANCED PROSTATE CANCER IN EARLY LIFE. Journal Of Urology 2023, 209: e1079. DOI: 10.1097/ju.0000000000003349.01.Peer-Reviewed Original ResearchManagement strategies for radio-recurrent prostate cancer: a comprehensive review
Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2023, 0: 0-0. DOI: 10.21037/tcr-24-245.Peer-Reviewed Original Research
2022
PD57-01 MULTI-INSTITUTIONAL ANALYSIS OF CLINICAL AND IMAGING RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS
Fang A, Shumaker L, Martin K, Onah O, Jackson J, Khajir G, Fan R, Soodana-Prakash N, Patel H, Vourganti S, Filson C, Sprenkle P, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. PD57-01 MULTI-INSTITUTIONAL ANALYSIS OF CLINICAL AND IMAGING RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS. Journal Of Urology 2022, 207: e959. DOI: 10.1097/ju.0000000000002637.01.Peer-Reviewed Original Research
2021
MP05-05 MULTI-INSTITUTIONAL ANALYSIS OF RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS
Fang A, Shumaker L, Khajir G, Fan R, Soodana-Prakash N, Patel H, Sprenkle P, Sonn G, Punnen S, Gupta G, Rais-Bahrami S. MP05-05 MULTI-INSTITUTIONAL ANALYSIS OF RISK FACTORS FOR DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITH PI-RADS 3 LESIONS. Journal Of Urology 2021, 206: e78-e78. DOI: 10.1097/ju.0000000000001972.05.Peer-Reviewed Original Research
2020
PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL
Sprenkle* P, Carroll P, Probst S, Gorin M, Rowe S, Pienta K, Pouliot F, Patnaik A, Preston M, Alva A, Siegel B, Morris M. PD38-05 CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED 18 F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000917.05.Peer-Reviewed Original Research
2019
PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER
Abello* A, Sprenkle P, Kenney P, Leapman M. PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555562.32224.0f.Peer-Reviewed Original Research
2018
How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy?
Lu A, Ghabili K, Nguyen K, Leapman M, Sprenkle P. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.Peer-Reviewed Original ResearchCancer detection rateFusion biopsyMulti-parametric MRILesion basisMRI-US fusion biopsyHistory of PCaHigh-grade cancerSignificant prostate cancerMRI-ultrasound fusion biopsyMpMRI studiesClinical suspicionPrimary outcomeSignificant PCaLesion biopsyDetection rateProstate cancerBiopsy coresBiopsyRegion of interestLesion targetingGenitourinary radiologistsCancerLesionsPatientsOne-quarter
2016
MRI-US fusion targeted biopsy results in patients without history of prostate biopsy.
Nawaf C, Rosoff J, Weinreb J, Lu A, Levi A, Humphrey P, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in patients without history of prostate biopsy. Journal Of Clinical Oncology 2016, 34: 150-150. DOI: 10.1200/jco.2016.34.2_suppl.150.Peer-Reviewed Original ResearchBiopsy-naive menMRI-US fusionGleason scoreProstate cancerMapping biopsyProstate biopsyCS prostate cancerPre-biopsy mpMRITemplate mapping biopsyLow-grade diseaseCancer detection rateMRI-ultrasound fusionBiopsy of lesionsMaximum Gleason scoreCS cancerPrevious biopsyPrior biopsyBiopsy resultsFusion biopsyInclusion criteriaMp-MRIPatient basisPatientsBiopsyCancer